Dapagliflozin/saxagliptin

Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth.
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.
Medical uses.
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus: